Ignite Creation Date:
2024-05-05 @ 4:58 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00357968
Status:
COMPLETED
Last Update Posted:
2010-08-31
First Post:
2006-07-26
Brief Title:
Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Protocol H7T-MC-TABLa PRasugrel IN Comparison to Clopidogrel for Inhibition of PLatelet Activation and AggrEgation PRINCIPLE - TIMI 44
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PRINCIPLE
Brief Summary:
The purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies inflammation and myocyte necrosis in subjects undergoing elective percutaneous coronary intervention PCI
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H7T-MC-TABL | OTHER | Eli Lilly and Company | None |